drugset / Trial / NCT01554371
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of eribulin (Halaven™) and cyclophosphamide (Cytoxan®) given together at different doses. This study will look at what effects, good and/or bad, that these drugs have on solid tumors. Eribulin is a drug that has been approved by the FDA for breast cancer that has spread to other parts of the body. Cyclophosphamide has been approved for different types of cancers (including breast cancer). However, the combination of eribulin and cyclophosphamide is considered experimental; that means this combination has not been approved by the FDA. The funding for this study is provided by Eisai Inc., the maker of eribulin.
Timeline
- Start
- 2012-03-27
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Subject | Eribulin | Small molecule | 1.1 mg/m2 | Intravenous |
| Subject | Eribulin | Small molecule | 1.4 mg/m2 | Intravenous |